Systematic Review and Meta-analysis: Loss of Response and Need for Dose Escalation of Infliximab and Adalimumab in Ulcerative Colitis.

Edo H J Savelkoul,Pepijn W A Thomas,Lauranne A A P Derikx,Nathan den Broeder,Tessa E H Römkens,Frank Hoentjen

Inflammatory bowel diseases（2022）

引用 4|浏览0

暂无评分

摘要

Annual loss of response was 10% for infliximab and 13% for adalimumab, with higher rates during the first year. Annual dose escalation rates were 14% (infliximab) and 21% (adalimumab), with clinical benefit in 72% and 52%, respectively. Uniform definitions are needed to facilitate more robust evaluations.

查看译文

关键词

anti-TNF,dose escalation,loss of response,ulcerative colitis

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要